Skip to main content
SpringerLink
Log in

Polycystic Ovary Syndrome and Metabolic Syndrome

  • Chapter
Insulin Resistance

Part of the book series: Contemporary Endocrinology ((COE))

The polycystic ovary syndrome (PCOS) is a very common disorder with important short-term and long-term consequences. Indeed, affected women manifest many clinical and biochemical features of metabolic syndrome, putting them at increased risk for diabetes and cardiovascular diseases. In the past 15 years, the key role of insulin resistance (IR) in the pathogenesis of PCOS has been stressed, and this common etiology between the two syndromes might account for their similarities. In fact, PCOS is considered a consequence of IR in the same way as metabolic syndrome, and women at risk for PCOS are also subject to the development of metabolic syndrome. Therefore, this chapter will explore the relationships between the metabolic syndrome and PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 2005; 6: 1012-22.

    PubMed  CAS  Google Scholar 

  2. Pesant MH, Baillargeon JP. Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome. Expert Rev Obstet Gynecol 2006;1: 81-92.

    Article  CAS  Google Scholar 

  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.

    Google Scholar 

  4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral IR, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38: 1165-74.

    Article  PubMed  CAS  Google Scholar 

  5. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41: 1257-66.

    Article  PubMed  CAS  Google Scholar 

  6. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for IR in the polycystic ovary syndrome. J Clin Invest 1995; 96: 801-10.

    Article  PubMed  CAS  Google Scholar 

  7. Ek I, Arner P, Bergqvist A, Carlstrom K, Wahrenberg H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to IR. J Clin Endocrinol Metab 1997; 82: 1147-53.

    Article  PubMed  CAS  Google Scholar 

  8. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 1996;81: 302-9.

    Article  PubMed  CAS  Google Scholar 

  9. Nahum R, Thong KJ, Hillier SG. Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod 1995;10: 75-81.

    Article  PubMed  CAS  Google Scholar 

  10. Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986;62: 904-10.

    Article  PubMed  CAS  Google Scholar 

  11. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998;83: 2001-5.

    Article  PubMed  CAS  Google Scholar 

  12. Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, Asano T, Fujishiro M, Legro RS, Kimball SR, Strauss JF, III, McAllister JM. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol 2005;19: 379-90.

    Article  PubMed  CAS  Google Scholar 

  13. Yki-Jarvinen H, Makimattila S, Utriainen T, Rutanen EM. Portal insulin concentrations rather than insulin sensitivity regulate serum sex hormone-binding globulin and insulin-like growth factor binding protein 1 in vivo. J Clin Endocrinol Metab 1995; 80: 3227-32.

    Article  PubMed  CAS  Google Scholar 

  14. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72: 83-9.

    PubMed  CAS  Google Scholar 

  15. Ciotta L, De Leo V, Farina M, Pafumi C, la Marca A, Cianci A. Endocrine and metabolic effects of insulin sensitizers in the treatment of patients with polycystic ovary syndrome and hyperinsulinaemia. Gynecol Obstet Invest 2001;51: 44-50.

    Article  PubMed  CAS  Google Scholar 

  16. Penna IAA, Canella PRB, Reis RM, Silva de Sa MF, Ferriani RA. Acarbose in obese patients with polycystic ovarian syndrome: a double-blind, randomized, placebo-controlled study. Hum Reprod 2005;20: 2396-401.

    Article  PubMed  CAS  Google Scholar 

  17. Veldhuis JD, Strauss JF, III, Silavin SL, Kolp LA. The role of cholesterol esterification in ovarian steroidogenesis: studies in cultured swine granulosa cells using a novel inhibitor of acyl coenzyme A: cholesterol acyltransferase. Endocrinology 1985;116: 25-30.

    PubMed  CAS  Google Scholar 

  18. Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997;82: 4075-9.

    Article  PubMed  CAS  Google Scholar 

  19. Bhatia V. IR in polycystic ovarian disease. South Med J 2005;98: 903-10.

    Article  PubMed  Google Scholar 

  20. VrbIkova J, C ibula D, D vorakova K, S tanicka S, Sindelka G, H ill M, F anta M, Vondra K, Skrha J. Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 2942-5.

    Article  PubMed  CAS  Google Scholar 

  21. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Tapanainen JS. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod 2000;15: 1266-74.

    Article  PubMed  CAS  Google Scholar 

  22. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Caruso A, Mancuso S, Lanzone A. Heterogeneity in beta cell activity, hepatic insulin clearance and peripheral insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1997;12: 1897-901.

    Article  PubMed  CAS  Google Scholar 

  23. Baillargeon JP, Carpentier AC. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007;88: 886-93.

    Article  PubMed  CAS  Google Scholar 

  24. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004;82: 893-902.

    Article  PubMed  CAS  Google Scholar 

  25. Baillargeon JP, Nestler JE. Polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin. J Clin Endocrinol Metab 2006;91: 22-4.

    Article  PubMed  CAS  Google Scholar 

  26. Kriketos AD, Greenfield JR, Peake PW, Furler SM, Denyer GS, Charlesworth JA, Campbell LV. Inflammation, insulin resistance, and adiposity: a study of first-degree relatives of type 2 diabetic subjects. Diabetes Care 2004;27: 2033-40.

    Article  PubMed  CAS  Google Scholar 

  27. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12: 2641-8.

    Article  PubMed  CAS  Google Scholar 

  28. Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998;95: 14956-60.

    Article  PubMed  CAS  Google Scholar 

  29. Baillargeon JP, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterized by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects. Diabetologia 2007;50: 2424-32.

    Article  PubMed  Google Scholar 

  30. Sam S, Legro RS, Bentley-Lewis R, D unaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90: 4797-802.

    Article  PubMed  CAS  Google Scholar 

  31. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, IR, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88: 2031-6.

    Article  PubMed  CAS  Google Scholar 

  32. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006;29: 270-80.

    PubMed  CAS  Google Scholar 

  33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.

    Article  Google Scholar 

  34. Reaven GM. Banting lecture 1988. Role of IR in human disease. Diabetes 1988; 37: 1595-607.

    Article  PubMed  CAS  Google Scholar 

  35. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90: 1929-35.

    Article  PubMed  CAS  Google Scholar 

  36. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52: 908-15.

    Article  PubMed  CAS  Google Scholar 

  37. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005; 106: 131-7.

    PubMed  Google Scholar 

  38. Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005;20: 2409-13.

    Article  PubMed  Google Scholar 

  39. Margolin E, Zhornitzki T, Kopernik G, Kogan S, Schattner A, Knobler H. Polycystic ovary syndrome in post-menopausal women-marker of the metabolic syndrome. Maturitas 2005;50: 331-6.

    Article  PubMed  CAS  Google Scholar 

  40. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A. Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci U S A 2006;103: 7030-5.

    Article  PubMed  CAS  Google Scholar 

  41. Korhonen S, Hippelainen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 2001;184: 289-96.

    Article  PubMed  CAS  Google Scholar 

  42. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333: 853-61.

    Article  PubMed  CAS  Google Scholar 

  43. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001;16: 1255-60.

    Article  PubMed  CAS  Google Scholar 

  44. Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, Welborn TA. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J Intern Med 2003;254: 555-63.

    Article  PubMed  CAS  Google Scholar 

  45. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10: 497-511.

    PubMed  CAS  Google Scholar 

  46. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with obesity. Int J Clin Pract 2005;59: 981-2.

    Article  PubMed  CAS  Google Scholar 

  47. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341: 1097-105.

    Article  PubMed  CAS  Google Scholar 

  48. Talbott E, Clerici A, B erga SL, K uller L, Guzick D, Detre K, Daniels T, Engberg RA. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 1998;51: 415-22.

    Article  PubMed  CAS  Google Scholar 

  49. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111: 607-13.

    Article  PubMed  CAS  Google Scholar 

  50. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, Kuller L. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15: 821-6.

    PubMed  CAS  Google Scholar 

  51. Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185: 227-39.

    Article  PubMed  CAS  Google Scholar 

  52. Rebuffe-Scrive M, Cullberg G, Lundberg PA, Lindstedt G, Bjorntorp P. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989;21: 391-7.

    Article  PubMed  CAS  Google Scholar 

  53. Holte J, Gennarelli G, Wide L, Lithell H, Berne C. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J Clin Endocrinol Metab 1998;83: 1143-50.

    Article  PubMed  CAS  Google Scholar 

  54. Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, Mattson LA, Crona N, Lundberg PA. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992;57: 505-13.

    PubMed  CAS  Google Scholar 

  55. Fisman EZ, Tenenbaum A, Pines A. Systemic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002;4: 464-70.

    Article  PubMed  Google Scholar 

  56. Mendelsohn ME. Protective effects of estrogen on the cardiovascular system. Am J Cardiol 2002;89: 12E-7E.

    Article  PubMed  CAS  Google Scholar 

  57. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352: 1223-36.

    Article  PubMed  CAS  Google Scholar 

  58. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18: 737-54.

    Article  PubMed  Google Scholar 

  59. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84: 165-9.

    Article  PubMed  CAS  Google Scholar 

  60. Harris MI, Hadden WC, Knowler WC, Bennett PH. P revalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yr. Diabetes 1987;36: 523-34.

    Article  PubMed  CAS  Google Scholar 

  61. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22: 141-6.

    Article  PubMed  CAS  Google Scholar 

  62. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005;90: 3236-42.

    Article  PubMed  CAS  Google Scholar 

  63. Solomon CG, Hu FB, Dunaif A, Rich-Edwards J, Willett WC, Hunter DJ, Colditz GA, Speizer FE, Manson JE. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286: 2421-6.

    Article  PubMed  CAS  Google Scholar 

  64. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001;24: 1050-2.

    Article  PubMed  CAS  Google Scholar 

  65. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000;52: 81-6.

    Article  CAS  Google Scholar 

  66. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101: 975-80.

    PubMed  CAS  Google Scholar 

  67. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the IR syndrome: the IR Atherosclerosis Study (IRAS). Circulation 2000;102: 42-7.

    PubMed  CAS  Google Scholar 

  68. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 1999;48: 437-41.

    Article  PubMed  CAS  Google Scholar 

  69. Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum C-reactive protein (CRP) levels and IR in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and IR. Horm Res 2004;62: 283-7.

    Article  PubMed  CAS  Google Scholar 

  70. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004;89: 2160-5.

    Article  PubMed  CAS  Google Scholar 

  71. Talbott EO, Zborowski JV, Boudreaux MY, McHugh-Pemu KP, Sutton-Tyrrell K, Guzick DS. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 6061-7.

    Article  PubMed  CAS  Google Scholar 

  72. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and lowgrade chronic inflammation. J Clin Endocrinol Metab 2004;89: 5592-6.

    Article  PubMed  CAS  Google Scholar 

  73. Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 1997;46: 454-7.

    Article  PubMed  CAS  Google Scholar 

  74. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996;45: 623-9.

    Article  CAS  Google Scholar 

  75. Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Rumley A, Lowe GD, Sattar N. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002;87: 3287-90.

    Article  PubMed  CAS  Google Scholar 

  76. Orio F Jr, Palomba S, Cascella T, De Simone B, Di Biase S, Russo T, Labella D, Zullo F, Lombardi G, Colao A. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 4588-93.

    Article  PubMed  CAS  Google Scholar 

  77. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103: 1410-5.

    PubMed  CAS  Google Scholar 

  78. Orio F Jr, Palomba S, Spinelli L, Cascella T, Tauchmanova L, Zullo F, Lombardi G, Colao A. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89: 3696-701.

    Article  PubMed  CAS  Google Scholar 

  79. Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004;175: 353-9.

    Article  PubMed  CAS  Google Scholar 

  80. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89: 5454-61.

    Article  PubMed  CAS  Google Scholar 

  81. Guzick DS. Cardiovascular risk in women with polycystic ovarian syndrome. Semin Reprod Endocrinol 1996;14: 45-9.

    Article  PubMed  CAS  Google Scholar 

  82. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000;20: 2414-21.

    PubMed  CAS  Google Scholar 

  83. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87: 2013-7.

    Article  PubMed  CAS  Google Scholar 

  84. Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15: 785-9.

    Article  PubMed  CAS  Google Scholar 

  85. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134: 61-71.

    PubMed  CAS  Google Scholar 

  86. Ghanim H, Garg R, Aljada A, Mohanty P, Kumbkarni Y, Assian E, Hamouda W, Dandona P. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86: 1306-12.

    Article  PubMed  CAS  Google Scholar 

  87. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P. Nuclear factorkappa B suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2001; 86: 3250-6.

    Article  PubMed  CAS  Google Scholar 

  88. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of IR. J Clin Endocrinol Metab 2001; 86: 517-20.

    Article  PubMed  CAS  Google Scholar 

  89. Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and IR. J Intern Med 2003; 254: 32-44.

    Article  PubMed  CAS  Google Scholar 

  90. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1175-80.

    Article  PubMed  CAS  Google Scholar 

  91. Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 36-42.

    Article  PubMed  CAS  Google Scholar 

  92. Schroeder BM, American College of Obstetricians and Gynecologists. A COG releases guidelines on diagnosis and management of polycystic ovary syndrome. Am Fam Physician 2003; 67: 1619-20.

    PubMed  Google Scholar 

  93. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 2005; 11: 126-34.

    Google Scholar 

  94. Gagnon C, Baillargeon JP. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007; 176: 933-8.

    PubMed  Google Scholar 

  95. Zimmerman J, Kaufmann NA, Fainaru M, Eisenberg S, Oschry Y, Friedlander Y, Stein Y. Effect of weight loss in moderate obesity on plasma lipoprotein and apolipoprotein levels and on high density lipoprotein composition. Arteriosclerosis 1984; 4: 115-23.

    PubMed  CAS  Google Scholar 

  96. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115 (Suppl 8A): 37S-41S.

    Article  PubMed  CAS  Google Scholar 

  97. Hoeger KM. Role of lifestyle modification in the management of polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006; 20: 293-310.

    Article  PubMed  Google Scholar 

  98. Bruner B, Chad K, C hizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab 2006; 31: 384-91.

    Article  PubMed  CAS  Google Scholar 

  99. Norman RJ, Noakes M, Wu R, Davies MJ, Moran L, Wang JX. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004;10: 267-80.

    Article  PubMed  Google Scholar 

  100. Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-20.

    Article  PubMed  CAS  Google Scholar 

  101. Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 3863-70.

    Article  PubMed  CAS  Google Scholar 

  102. Turner RC, Holman RR, Stratton IM, Cull CA, Matthews DR, Manley SE, Frighi V, Wright D, Neil A, Kohner E, McElroy H, Fox C, Hadden D. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-65.

    Article  Google Scholar 

  103. Lemay A, Dodin S, Turcot L, Dechene F, Forest JC. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and IR. Hum Reprod 2006; 21: 121-8.

    Article  PubMed  CAS  Google Scholar 

  104. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89: 1592-7.

    Article  PubMed  CAS  Google Scholar 

  105. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr Jones DW, Materson BJ, Oparil S, Wright JT, Jr Roccella EJ. S eventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.

    Article  PubMed  CAS  Google Scholar 

  106. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28: 341-59.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Endocrinology, Université de Sherbrooke, Sherbrooke, Québec, Canada

    Marie-Hélène Pesant MD & Jean-Patrice Baillargeon MD

Authors
  1. Marie-Hélène Pesant MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Patrice Baillargeon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pediatrics, University of Colorado Denver, Aurora, CO, 80045, USA

    Philip Scott Zeitler  & Kristen J. Nadeau  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science + Business Media, LLC

About this chapter

Cite this chapter

Pesant, MH., Baillargeon, JP. (2008). Polycystic Ovary Syndrome and Metabolic Syndrome. In: Zeitler, P.S., Nadeau, K.J. (eds) Insulin Resistance. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-192-5_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-192-5_14

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-875-1

  • Online ISBN: 978-1-59745-192-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation